Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03690388 · ClinicalTrials.gov registry record · Phase 3
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
A Phase 3 study of Differentiated Thyroid Cancer, sponsored by Exelixis.
- Active
- Registry status
- Phase 3
- Development phase
- 187
- Enrollment target
- 20
- Study locations
NCT03690388 is a Phase 3 study of Differentiated Thyroid Cancer that is active but no longer recruiting, run by Exelixis. The registered enrollment target is 187 participants, above the 65-participant average among 5 other Differentiated Thyroid Cancer trials with a reported enrollment target (188% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT03690388, a Phase 3 study of Differentiated Thyroid Cancer, is active but no longer recruiting, sponsored by Exelixis.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 187 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid Cancer (DTC) who have progressed after prior vascular endothelial growth factor receptor (VEGFR)-Targeted therapy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Cabozantinib
Study Locations (20)
California
- Exelixis Clinical Site #2 - Newport Beach
- Exelixis Clinical Site #98 - Sacramento
- Exelixis Clinical Site #69 - San Francisco
- Exelixis Clinical Site #10 - Stanford
- Exelixis Clinical Site #3 - Torrance
Florida
- Exelixis Clinical Site #94 - Miami
- Exelixis Clinical Site #93 - Orlando
- Exelixis Clinical Site #6 - Tampa
Michigan
- Exelixis Clinical Site #80 - Ann Arbor
- Exelixis Clinical Site #78 - Detroit
- Exelixis Clinical Site #22 - Detroit
Missouri
- Exelixis Clinical Site #63 - Columbia
- Exelixis Clinical Site #42 - St Louis
Colorado
- Exelixis Clinical Site #9 - Aurora
Connecticut
- Exelixis Clinical Site #21 - New Haven
District of Columbia
- Exelixis Clinical Site #4 - Washington D.C.
Illinois
- Exelixis Clinical Site #164 - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 187 participants |
| Start Date | 2018-10-05 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03690388
The ClinicalTrials.gov registry entry for NCT03690388 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 187 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 65-participant average among 5 other Differentiated Thyroid Cancer trials with a reported enrollment target (188% higher). The listed sponsor is Exelixis, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Differentiated Thyroid Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03690388 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT03690388 about?
NCT03690388 is a clinical study titled "A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy". The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid Cancer (DTC) who have progressed after prior vascular endothelial growth fac...
What is the current status of trial NCT03690388?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 187 participants. The study started on 2018-10-05. Estimated completion is 2026-07-31.
What conditions does trial NCT03690388 study?
This clinical trial studies the following conditions: Differentiated Thyroid Cancer.
What interventions are being tested in trial NCT03690388?
The interventions under investigation include: Placebo (DRUG), Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT03690388?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03690388 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Differentiated Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
COMPLETED · Phase 3
-
Targeted Therapy to Increase RAI Uptake in Metastatic DTC
RECRUITING
-
Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)
RECRUITING · Phase 2
-
Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer
RECRUITING · Phase 2
-
Lenvatinib in Locally Advanced Invasive Thyroid Cancer
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.